Clinical trials: Bladder Cancer, completed
Urinary Bladder Neoplasms
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone.
- Trial name
- SunRISe-4 (NCT04919512)
- Testing
- TAR-200, Cetrelimab
- Where
- 109 sites in United States, Belgium and 8 more
- Volunteers
- 163 people
- Sponsor
- Janssen Research & Development, LLC
Bladder Cancer
Comparison of Apixaban Versus Enoxaparin
The goal of this randomized trial is to compare bladder cancer patient experiences taking prophylactic anticoagulation at home after surgery to remove their bladder.
- Trial name
- CARE (NCT06243510)
- Testing
- apixaban, enoxaparin
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Bladder Cancer
Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer
The purpose of this study is to compare patient tumor tissue before and after treatment with chemotherapy plus celecoxib. Investigators will look at gene expression, to see what effect celecoxib may have on tumor cells.
- Trial name
- BLAST (NCT02885974)
- Testing
- Celecoxib, Gemcitabine, Cisplatin
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Baylor College of Medicine
Bladder Cancer, Bladder Cancer Recurrence
Predictive Value of E-cadherin, β-catenin and SOX4 in Recurrence and/or Progression of Non-muscle Invasive Urinary Bladder Transitional Cell Carcinoma. A Retrospective Study
Bladder cancer is common tumor in which recurrence and/or progression in patients undergoing TUR has been reported to range between 30% and 80% in patients with NMIBC TCC.
- Trial name
- NCT07657299
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Urinary Bladder Tumour
Urinary Markers by SpectrosCopy: Diagnostic Aid in oncologY - Application to Urological Cancers
This study aims to evaluate the performance of vibrational spectroscopy (Infrared and Raman spectroscopy techniques) in bladder cancer diagnosis using urine samples.
- Trial name
- MUSCADE (NCT06087016)
- Testing
- Urine vibrational analysis
- Where
- France
- Volunteers
- 899 people
- Sponsor
- CHU de Reims
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Transurethral Resection of Bladder Tumor
Evaluation of the Role of Early Second Look TURBT in Management of High Risk Non Muscle Invasive Bladder Cancer
The aim is to evaluate the intraoperative, postoperative and pathologic findings of early second look TURBT and the factors affecting these findings to assess the value of early second TURBT in the management of high risk NMIBC.
- Trial name
- NCT07642102
- Testing
- early second look transurethral resection of bladder tumor
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Ain Shams University
Melanoma, Non-Small Cell Lung Cancer
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in…
- Conditions
- Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer
- Trial name
- NCT03289962
- Testing
- Autogene cevumeran, Atezolizumab
- Where
- 33 sites in United States, Belgium and 6 more
- Volunteers
- 273 people
- Sponsor
- Genentech, Inc.
Urothelial Carcinoma of the Bladder
Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)
The aim of this study is to evaluate a risk-adapted approach to the treatment of muscle invasive bladder cancer. Each baseline transuretheral resection of bladder tumor (TURBT) sample will be sequenced while proceeding with…
- Trial name
- NCT02710734
- Testing
- Methotrexate, Vinblastine, Doxorubicin
- Where
- 4 sites in United States
- Volunteers
- 78 people
- Sponsor
- Fox Chase Cancer Center
Bladder Cancer
Trial to Compare Robotically Assisted Radical Cystectomy With Open Radical Cystectomy
This is a prospective multicentre randomised controlled trial comparing the outcomes from Intracorporeal RARC (iRARC) with open radical cystectomy (ORC) in patients with bladder cancer.
- Trial name
- iROC (NCT03049410)
- Testing
- Intracorporeal Robot Assisted Radical Cystectomy, Open Radical Cystectomy
- Where
- 8 sites in United Kingdom
- Volunteers
- 339 people
- Sponsor
- University College, London
Multiparametric, Magnetic Resonance Imaging
Multiparametric MRI for Bladder Cancer: Validation of VI-RADS for the Detection of Muscle Invasive Bladder Cancer
This research aimed to determine how accurately multiparametric magnetic resonance imaging (MRI), when interpreted using the VI-RADS scoring system, can distinguish between invasive and non-invasive bladder cancer.
- Conditions
- Multiparametric, Magnetic Resonance Imaging, Validation, Vesical Imaging Reporting and Data System (VI-RADS)
- Trial name
- NCT07578233
- Testing
- Magnetic resonance imaging
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Prostate Cancer (Adenocarcinoma), Bladder Cancer
Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)
This trial tests if AI can help make medical info clear and readable. Many patients struggle to find medical informations that easy to read and understand from verified medical sources.
- Conditions
- Prostate Cancer (Adenocarcinoma), Bladder Cancer, Kidney Cancers, Testis Cancer
- Trial name
- NCT07568444
- Testing
- Pub2Post
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Bladder Cancer
The Personal Patient Profile Decision Support for Patients With Bladder Cancer
There is a pressing need to develop a personalized, value-based decisional tool for bladder cancer patients undergoing radical cystectomy (bladder removal) and urinary diversion to help them with communication with the…
- Trial name
- P3BC (NCT05033067)
- Testing
- P3BC
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Breast Cancer, Bladder Cancer
Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment
The primary objectives of this study are (1) to compare the incidence of breast cancer, by insulin use at cohort entry, among females with type 2 diabetes who are new users of dapagliflozin and females who are new users of…
- Trial name
- NCT02695121
- Where
- 4 sites in United States, Netherlands and 1 more
- Volunteers
- 2,133,575 people
- Sponsor
- AstraZeneca
Bladder Tumor (TURBT)
Holmium Laser En-Bloc Resection Versus Conventional Transurethral Resection of Bladder Tumors for Treatment of Non-muscle- Invasive Bladder Cancer
This study is a prospective randomized controlled trial comparing holmium laser en-bloc resection of bladder tumor (HoLERBT) with conventional transurethral resection of bladder tumor (cTURBT) in patients with suspected…
- Trial name
- NCT07534631
- Testing
- Holmium Laser En-Bloc Resection of Bladder Tumor, Conventional Transurethral Resection of Bladder Tumor
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Beni-Suef University
Bladder Cancer, Radical Cystectomy
Impact Advanced Recovery® for Radical Cystectomy (RC) Patients: a Pilot Study
The purpose of this study is determine if using Impact Advanced Recovery® before and after RC surgery helps reduce surgical complications.
- Conditions
- Bladder Cancer, Radical Cystectomy, Urinary Bladder Neoplasms, Surgery
- Trial name
- NCT01868087
- Testing
- Boost Plus®, Impact Advanced Recovery®
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jill Hamilton-Reeves, PhD RD LD
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Non-Small Cell Lung Cancer, Malignant Melanoma
Phase Ib of L-NMMA and Pembrolizumab
The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Non-Small Cell Lung Cancer, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma
- Trial name
- NCT03236935
- Testing
- L-NMMA, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Methodist Hospital Research Institute
Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell…
- Conditions
- Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder
- Trial name
- NCT05077709
- Testing
- IO102-IO103 in combination with pembrolizumab
- Where
- 21 sites in United States, Spain and 1 more
- Volunteers
- 63 people
- Sponsor
- IO Biotech
Renal Cell Carcinoma, Bladder Cancer
Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside
Immune checkpoint inhibitors (ICIs) are largely prescribed in a growing number of cancer diseases and at earlier stages (non metastatic cancer).
- Conditions
- Renal Cell Carcinoma, Bladder Cancer, MSI-H Cancer, Cancer
- Trial name
- VICKI (NCT06020651)
- Testing
- Arterial Doppler for Flow Mediated Reserve measurement
- Where
- France
- Volunteers
- 39 people
- Sponsor
- Institut Mutualiste Montsouris
Bladder Cancer, Biliary Tract Cancer
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
In DESTINY-Pan-Tumor [DP-02], DESTINY CRC02 [DC-02], and DESTINY-Lung01 [DL-01], T-DXd demonstrated tumor response across a broad range of HER2-expressing solid tumors, particularly IHC3+ patients.
- Conditions
- Bladder Cancer, Biliary Tract Cancer, Cervical Cancer, Endometrial Cancer
- Trial name
- NCT06973161
- Where
- 27 sites in United States, Austria and 10 more
- Volunteers
- 140 people
- Sponsor
- AstraZeneca